Skip to content

A clinical study to evaluate teeth whitening effectiveness of a new mouthwash

A double blind, single centric, randomized 3 arm parallel study to evaluate the efficacy and safety of Gurunanda Whitening mouthwash with enzymes in the management of improvement in tooth shade, reduction of surface stains and prevention of new stains - NIL

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/03/082282
Enrollment
120
Registered
2025-03-13
Start date
Unknown
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K089- Disorder of teeth and supporting structures, unspecified

Interventions

Intervention1: Gurunanda Whitening mouthwash with enzymes: 20 ml mouthwash twice a day orally for 6 weeks Control Intervention1: Therabreath Whitening Fresh Breath Mouthwash: 20 ml mouthwash twice a d

Sponsors

GURUNANDA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Adult male or female subjects 2.Subjects with atleast 20 permanent teeth excluding third molar 3.Non-smokers with good oral and general health 4.All 6 anterior maxillary teeth free of caries or restorations 5.Subjects having teeth shades of A2 or darker with no cervical lesions or prosthodontics treatments and with no periodontal disease 6.Subjects should not use mouthwash 1 week prior to screening and during the whole course of the study 7.All subjects should use same toothpaste during the entire course of the study 8.Able to communicate adequately with the investigator and to comply with the requirements for the entire study 9.Subjects should not have history of periodontal therapy one month prior to screening 10.Patient should be able to give written informed consent prior to participating in the study 11.Will not use other teeth whitening product(s) during the duration of the study

Exclusion criteria

Exclusion criteria: 1.Individuals with discolored teeth (eg:- tetracycline and fluorosis). 2.Subjects having intrinsic stains. 3.Steroidal anti-inflammatory drugs, NSAIDs one month prior to screening. 4.Concomitant diseases (i.e. cancer, kidney diseases, liver diseases, neurological diseases, diabetes, gastritis psychiatric diseases, blood disorders, gastrointestinal diseases). 5.Subjects with known sensitivity or oral mucosal tissue reaction to any components of the investigational product. 6.Pregnancy and breastfeeding women. 7.Participation in concomitant interventional clinical study during the previous 30 days. 8.Active oral infections, untreated cavities, or periodontal disease. 9.Presence of restorations on front teeth (e.g., crowns, veneers, or composite fillings) that could affect whitening results. 10.Recent dental procedures (e.g., scaling, polishing, or whitening) within the last 4 weeks. 11.Concurrent use of whitening products or treatments within the past 4 weeks. 12.Heavy tobacco use, including cigarettes, cigars, or smokeless tobacco. 13.Consumption of stain-causing substances (e.g., red wine, coffee, tea) that cannot be avoided during the study period. 14.Use of medications that may affect tooth discoloration (e.g., tetracyclines, chlorhexidine). 15.Presence of orthodontic appliances, except for removable retainers. 16.Signs of advanced enamel wear, dentin exposure, or tooth fractures.

Design outcomes

Primary

MeasureTime frame
Improvement of tooth whiteningTimepoint: Screening, week 2,4 and 6.

Secondary

MeasureTime frame
1) Reduction of surface stains 2) Prevention of new stainTimepoint: Screening, week 2,4 and 6.

Countries

India

Contacts

Public ContactDr Deepa Subramanian

Syncretic Clinical Research Services Pvt Ltd

deepa@syncretic.in9972598010

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026